

Top 200 Drugs by Retail Sales in 2023

Compiled and Produced by Ryan E. Williams and Hayden M. Leatherwood from the Njarðarson Group (The University of Arizona)

1 Keytruda (Pembrolizumab) \$25.01 Billion Oncology Cardiology/Vascular Diseases	2 Eliquis (Apixiban) \$16.93 Billion Cardiology/Vascular Diseases	3 Ozempic (Semaglutin) \$18.48 Billion Cardiology/Vascular Diseases	4 Humira (Adalimumab) \$14.49 Billion Immunology	5 Biktarvy (Biktarvy/Emtricitabine/Tenofovir Alafenamide) \$11.852 Billion Rare Diseases	6 Dupixent (Dupilumab) \$11.565 Billion Immunology	7 Stelara (Ustekinumab) \$11.297 Billion Immunology	8 Comirnaty (COVID-19 Vaccine, mRNA) \$11.220 Billion Immunology	9 Jardiance (Empagliflozin) \$10.600 Billion Diabetes	10 Opdivo (Nivolumab) \$10.010 Billion Immunology	11 Darzalex (Daratumumab) \$9.744 Billion Immunology	12 Eylea (Aflibercept) \$9.225 Billion Ophthalmology	13 Trikafta (Elexcaftor/Tezacaftor/Vaccinia) \$8.864 Billion Rare Diseases	14 Gardasil (HPV Quadrivalent Vaccine) \$8.864 Billion Infectious Diseases	15 Skyrizi (Risankizumab) \$7.763 Billion Immunology	16 Ocrevus (Ocrelizumab) \$7.403 Billion Immunology	17 Trulicity (Dulaglutin) \$7.132 Billion Diabetes	18 Insulin (Insulin) \$6.979 Billion Diabetes	19 Imbruvica (Ibrutinib) \$6.860 Billion Oncology	20 Xarelto (Rivaroxaban) \$6.793 Billion Cardiology/Vascular Diseases
21 Prevnar Family (Pneumococcal 7-Valent Conjugate) \$6.440 Billion Infectious Diseases	22 Revlimid (Lenalidomide) \$6.179 Billion Oncology	23 Entresto (Sacubitril/Valsartan) \$6.035 Billion Cardiology/Vascular Diseases	24 Xtandi (Enzalutamide) \$5.971 Billion Oncology	25 Farigra (Dapagliflozin) \$5.963 Billion Diabetes	26 Taqrisso (Ticagrelor) \$5.799 Billion Oncology	27 Botox (OnabotulinumtoxinA) \$5.673 Billion Neurology	28 Entyvio (Vedolizumab) \$5.380 Billion Immunology	29 Mounjaro (Tirzepatide) \$5.163 Billion Diabetes	30 Cosentyx (Secukinumab) \$4.980 Billion Immunology	31 Hemlibra (Emicizumab) \$4.817 Billion Rare Diseases	32 Ibrance (Palbociclib) \$4.753 Billion Oncology	33 Enbrel (Etanercept) \$4.527 Billion Immunology	34 Perjeta (Pertuzumab) \$4.371 Billion Oncology	35 Tecentriq (Atezolizumab) \$4.369 Billion Oncology	36 Imfinzi (Durvalumab) \$4.237 Billion Oncology	37 Immunoglobulin (Immunoglobulin) \$4.210 Billion Immunology	38 NovoRapid (Insulin Aspart) \$4.177 Billion Diabetes	39 Invega Sustenna (Paliperidone Palmitate) \$4.115 Billion Neurology	40 Prolia (Denosumab) \$4.049 Billion Musculoskeletal
41 Lynparza (Olaparib) \$4.010 Billion Oncology	42 Xolair (Omalizumab) \$3.987 Billion Immunology	43 Rinvoq (Upadacitinib) \$3.969 Billion Immunology	44 Verzenio (Tucatinib) \$3.863 Billion Oncology	45 Ofev (Nintedanib) \$3.726 Billion Respiratory Diseases	46 Shingrix (Zoster Vaccine Recombinant, Adjuvanted) \$3.717 Billion Immunology	47 Orencia (Abatacept) \$3.601 Billion Immunology	48 Pomalyst (Pomalidomide) \$3.441 Billion Oncology	49 Vyndaqel (Tofacitinib) \$3.321 Billion Immunology	50 Simponi (Risankizumab) \$3.199 Billion Immunology	51 Tremfya (Galcitumab) \$3.147 Billion Immunology	52 Soliris (Eculizumab) \$3.145 Billion Immunology	53 Actemra (Tocilizumab) \$3.051 Billion Immunology	54 Yvyanse (Lidexifenamine) \$2.978 Billion Oncology	55 Ultomiris (RimabotulinumtoxinB) \$2.965 Billion Immunology	56 Lenvima (Lenvatinib) \$2.868 Billion Oncology	57 Taltz (Tegobixumab) \$2.759 Billion Immunology	58 Vraylar (Cariprazine) \$2.739 Billion Oncology	59 Vabysmo (Vismodegib) \$2.714 Billion Oncology	60 Rybelsus (Eliquis) \$2.725 Billion Diabetes
61 Calquence (Acadysma) \$2.514 Billion Oncology	62 Eylea (Aflibercept) \$2.387 Billion Ophthalmology	63 Trelegra Ellipta (Elexcaftor/Tenofvir Alafenamide) \$2.376 Billion Respiratory Diseases	64 Symbicort (Budesonide/Formoterol) \$2.362 Billion Oncology	65 Ehertu (Trafuzamide Dexamethasone) \$2.349 Billion Oncology	66 Venclexta (Venetoclax) \$2.289 Billion Oncology	67 Kadcyla (Trastuzumab Emtansine) \$2.280 Billion Oncology	68 Promacta (Ezetimibe) \$2.269 Billion Oncology	69 Cimzia (Certolizumab Pegol) \$2.253 Billion Immunology	70 Yervoy (Ipilimumab) \$2.238 Billion Immunology	71 Rimecic (Rimegepant) \$2.233 Billion Immunology	72 Xgeva (Denosumab) \$2.212 Billion Immunology	73 Januvia (Sitagliptin) \$2.189 Billion Diabetes	74 Otezla (Apremilast) \$2.188 Billion Immunology	75 Vekury (Ertugliflozin) \$2.184 Billion Diabetes	76 Kesimpta (Opicinumab) \$2.171 Billion Immunology	77 Kisqali (Ribociclib) \$2.090 Billion Oncology	78 Reutti (Ibragadol) \$2.099 Billion Neurology	79 Genvoxa (Ertugliflozin/Tenofvir Alafenamide) \$2.060 Billion Oncology	80 Lucentis (Ranibizumab) \$2.029 Billion Ophthalmology
81 Descovy (Emtricitabine/Tenofovir Alafenamide) \$1.983 Billion Infectious Diseases	82 Opsumit (Macitentan) \$1.972 Billion Cardiology/Vascular Diseases	83 Dovato (Dolutegravir/Lamivudine) \$1.963 Billion Infectious Diseases	84 Sprycel (Dasatinib) \$1.930 Billion Oncology	85 Tafinlar (Dabrafenib/Trafetinib) \$1.922 Billion Oncology	86 MabThera (Rituximab) \$1.891 Billion Oncology	87 Herceptin (Trastuzumab) \$1.866 Billion Oncology	88 Tysabri (Natalizumab) \$1.876 Billion Immunology	89 Prezista (Darunavir/Cobicistat) \$1.854 Billion Immunology	90 Tasigna (Nilotinib) \$1.848 Billion Immunology	91 Bridion (Sugammadex) \$1.842 Billion Immunology	92 Ingrezza (Valproic Acid) \$1.836 Billion Neurology	93 Avastin (Bevacizumab) \$1.825 Billion Oncology	94 Trajenta (Linagliptin/Metformin) \$1.815 Billion Diabetes	95 Gilenya (Fingolimod) \$1.811 Billion Immunology	96 Nucala (Mepolizumab) \$1.786 Billion Immunology	97 Alecensa (Alectinib) \$1.742 Billion Oncology	98 Spiranza (Nivolumab) \$1.741 Billion Immunology	99 Jakavi (Ruxofitinib) \$1.720 Billion Oncology	100 Lixiana (Edoxaban) \$1.726 Billion Immunology
101 Xeljanz (Tofacitinib) \$1.703 Billion Immunology	102 Zyprexa (Olanzapine) \$1.694 Billion Neurology	103 Triumeq (Abacavir/Dolutegravir/Lamivudine) \$1.664 Billion Infectious Diseases	104 Humalog (Insulin Lispro) \$1.663 Billion Diabetes	105 Erysdi (Risipirone) \$1.646 Billion Neurology	106 Repatha (Evolocumab) \$1.635 Billion Cardiology/Vascular Diseases	107 Upravi (Seligynil) \$1.582 Billion Cardiology/Vascular Diseases	108 Creon (Pancrelipase) \$1.572 Billion Rare Diseases	109 Lipitor (Atorvastatin) \$1.559 Billion Cardiology/Vascular Diseases	110 Fasena (Benralumab) \$1.553 Billion Respiratory Diseases	111 Eplusla (Eplorivir/Vedolizumab) \$1.537 Billion Immunology	112 Lantus (Insulin Glargine) \$1.532 Billion Diabetes	113 Yescarta (Axicicabtagene Caricel) \$1.499 Billion Oncology	114 Tivicy (Dolutegravir) \$1.495 Billion Infectious Diseases	115 Saxenda (Lorcaserin) \$1.495 Billion Nutritional Deficiency	116 Kyprolis (Carboplatin) \$1.478 Billion Oncology	117 Nplate (Romiplostim) \$1.477 Billion Immunology	118 Benlysta (Belimumab) \$1.456 Billion Immunology	119 Mavyret (Glecaprevir/Pasirevator) \$1.430 Billion Infectious Diseases	120 Lagevrio (Migalastat) \$1.429 Billion Infectious Diseases
121 Brukina (Zinc Finger Nucleotidase Inhibitor) \$1.396 Billion Rare Diseases	122 Juvederm (Hyaluronic Acid) \$1.376 Billion Dermatology	123 Spiriva (Tiotropium) \$1.372 Billion Respiratory Diseases	124 Prograf (Cyclosporine) \$1.365 Billion Immunology	125 Aranesp (Darbepoetin Alfa) \$1.362 Billion Immunology	126 Activase (Alteplase/Tenecteplase) \$1.360 Billion Cardiology/Vascular Diseases	127 Ilaris (Canakinumab) \$1.355 Billion Immunology	128 Abilify Maintena (Aripiprazole) \$1.350 Billion Immunology	129 Odefsey (Emtricitabine/Rilpivirine/Tenofovir Alafenamide) \$1.330 Billion Infectious Diseases	130 Adempas (Riociclat) \$1.338 Billion Cardiology/Vascular Diseases	131 Brillinta (Iscagator) \$1.324 Billion Cardiology/Vascular Diseases	132 Sandostatin (Octreotide) \$1.314 Billion Immunology	133 Mirena (Levonorgestrel) \$1.311 Billion Immunology	134 Phesgo (Pertuzumab/Trastuzumab/Trastuzumab Derivative) \$1.299 Billion Oncology	135 Betanis (Metformin) \$1.283 Billion Diabetes	136 Nexgard (Eprazinone) \$1.280 Billion Immunology	137 Paxlovid (Ritonavir/Simeprevir) \$1.280 Billion Infectious Diseases	138 Xywav (Cis, Arg, and His Oxycodone) \$1.272 Billion Immunology	139 Victoza (Liraglutide) \$1.259 Billion Diabetes	140 Seretide (Salmeterol) \$1.229 Billion Immunology
141 Austedo (Dehydroepiandrosterone) \$1.225 Billion Neurology	142 Evenity (Romosozumab) \$1.224 Billion Musculoskeletal	143 Jynarque (Ibikmatinib) \$1.223 Billion Cardiology/Vascular Diseases	144 Reblozyl (Luspatercept) \$1.220 Billion Immunology	145 AbraXane (Pomalidomide) \$1.216 Billion Oncology	146 Loxenol (Enxapipin) \$1.214 Billion Cardiology/Vascular Diseases	147 Zolgensma (Onasemnogene Apheresis Concentrate) \$980 Million Rare Diseases	148 Toujeo (Insulin Glargine) \$974 Million Diabetes	149 Relvar (Fluciclovone Folate) \$971 Million Immunology	150 Janumet (Sitagliptin/Metformin) \$952 Million Diabetes	151 Talkhzyro (Lansoprazole/Ramipril) \$945 Million Gastrointestinal Diseases	152 Vectibix (Panitumumab) \$942 Million Oncology	153 Strensiq (Aldesleukin) \$940 Million Immunology	154 Somatuline (Lacosamide) \$928 Million Oncology	155 Edurant (Bicitarabine) \$922 Million Immunology	156 Tresiba (Insulin Degludec) \$919 Million Diabetes	157 Covid-19 Vaccine (Ad26.COV2.S (Recombinant)) \$918 Million Immunology	158 Crestor (Rosuvastatin) \$899 Million Immunology	159 Linzess (Linaclotide) \$887 Million Gastrointestinal Diseases	160 Crysvita (Ibrutinib) \$887 Million Oncology
161 Fabrazyme (Agalsidase Beta) \$1.069 Billion Immunology	162 Trodelyq (Sacubitril/Valsartan) \$1.063 Billion Cardiology/Vascular Diseases	163 Inlyta (Axitinib) \$1.036 Billion Oncology	164 Aubagio (Teriflunomide) \$1.020 Billion Neurology	165 Plavix (Clopidogrel) \$1.023 Billion Cardiology/Vascular Diseases	166 Tecfidera (Dimethyl Fumarate) \$1.012 Billion Immunology	167 Pluvicto (Lutetium-177 viplovotide Tetraxetan) \$980 Million Oncology	168 Cyramza (Ramucicab) \$974 Million Oncology	169 Polivy (Polatumumab Vedotin-pilg) \$971 Million Immunology	170 Zoladex (Goserelin) \$952 Million Diabetes	171 Nexium (Esomeprazole) \$945 Million Gastrointestinal Diseases	172 Nubeqa (Darolutamide) \$942 Million Oncology	173 Gazyva (Obinutuzumab) \$940 Million Immunology	174 Nurtec ODT (Rimegepant) \$928 Million Immunology	175 Olumiant (Baliciclib) \$922 Million Immunology	176 Blinicyto (Blinatumumab) \$919 Million Immunology	177 Bexsero (Meningococcal Vaccine) \$918 Million Immunology	178 Praxada (Dabigatran Etexilate) \$899 Million Immunology	179 Albumin (Albumin) \$887 Million Immunology	180 Zytiga (Abiraterone Acetate) \$887 Million Oncology
181 Libtayo (Campylomycin) \$863 Million Oncology	182 Vemlidy (Tenofovir Disoproxil) \$842 Million Infectious Diseases	183 Humulin (Insulin Human) \$832 Million Diabetes	184 Epidiolex (Cannabidiol) \$845 Million Neurology	185 Myzyme (Agalsidase Alfa) \$845 Million Diabetes	186 Nexplanon (Etonogestrel) \$830 Million Women's Health	187 Advate (Antihemophilic Factor Recombinant) \$818 Million Rare Diseases	188 Ubrevy (Bimegepant) \$815 Million Neurology	189 Avonex (Interferon Beta-1a) \$811 Million Neurology	190 Ventolin (Albuterol) \$808 Million Respiratory Diseases	191 Kogenate (Antihemophilic Factor Recombinant) \$800 Million Rare Diseases	192 Alprolix (Antihemophilic Factor Recombinant) \$786 Million Rare Diseases	193 Concerta (Methylphenidate) \$783 Million Neurology	194 Takecab (Vincapristin) \$780 Million Gastrointestinal Diseases	195 Synagis (Palivizumab) \$778 Million Immunology	196 Cabenuva (Cabotegravir/Rilpivirine) \$764 Million Infectious Diseases	197 Sulperazon (Cefepime/Albuciclan) \$757 Million Infectious Diseases	198 Adcetris (Brentuximab Vedotin) \$744 Million Oncology	199 Cerezyme (Imiglucerase) \$741 Million Immunology	200 Norvasc (Amlodipine) \$732 Million Cardiology/Vascular Diseases

Key: Oncology, Immunology, Infectious Diseases, Neurology, Diabetes, Cardiology/Vascular Diseases, Rare Diseases, Respiratory Diseases, Hematology, Gastrointestinal Diseases, Musculoskeletal, Other